Metabolic Reprogramming in Triple-Negative Breast Cancer
Metabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells exhibit distinct metabolic phenotypes to fuel their proliferation and progression. The significant advancements made in the area of metabolic reprogramming make possible new strategies for overcoming malignant can...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00428/full |
| _version_ | 1817987124147781632 |
|---|---|
| author | Xiangyu Sun Mozhi Wang Mengshen Wang Xueting Yu Jingyi Guo Tie Sun Xinyan Li Litong Yao Haoran Dong Yingying Xu |
| author_facet | Xiangyu Sun Mozhi Wang Mengshen Wang Xueting Yu Jingyi Guo Tie Sun Xinyan Li Litong Yao Haoran Dong Yingying Xu |
| author_sort | Xiangyu Sun |
| collection | DOAJ |
| description | Metabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells exhibit distinct metabolic phenotypes to fuel their proliferation and progression. The significant advancements made in the area of metabolic reprogramming make possible new strategies for overcoming malignant cancer, including triple-negative breast cancer. Triple-negative breast cancer (TNBC) is associated with high histologic grade, aggressive phenotype, and poor prognosis. Even though triple-negative breast cancer patients benefit from standard chemotherapy, they still face high recurrence rates and are more likely to develop resistance to chemotherapeutic drugs. Therefore, there is an urgent need to explore vulnerabilities of triple-negative breast cancer and develop novel therapeutic drugs to improve clinical outcomes for triple-negative breast cancer patients. Metabolic reprogramming may provide promising therapeutic targets for the treatment of triple-negative breast cancer. In this paper, we primarily discuss how triple-negative breast cancer cells reprogram their metabolic phenotype and that of stromal cells in the microenvironment to survive under nutrient-poor conditions. Considering that metastasis and chemoresistance are the main contributors to mortality in triple-negative breast cancer patients, we also focus on the role of metabolic adaption in mediating metastasis and chemoresistance of triple-negative breast cancer tumors. |
| first_indexed | 2024-04-14T00:17:52Z |
| format | Article |
| id | doaj.art-41f506536059480b98b8df2253c36db9 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-14T00:17:52Z |
| publishDate | 2020-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-41f506536059480b98b8df2253c36db92022-12-22T02:23:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-03-011010.3389/fonc.2020.00428526102Metabolic Reprogramming in Triple-Negative Breast CancerXiangyu SunMozhi WangMengshen WangXueting YuJingyi GuoTie SunXinyan LiLitong YaoHaoran DongYingying XuMetabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells exhibit distinct metabolic phenotypes to fuel their proliferation and progression. The significant advancements made in the area of metabolic reprogramming make possible new strategies for overcoming malignant cancer, including triple-negative breast cancer. Triple-negative breast cancer (TNBC) is associated with high histologic grade, aggressive phenotype, and poor prognosis. Even though triple-negative breast cancer patients benefit from standard chemotherapy, they still face high recurrence rates and are more likely to develop resistance to chemotherapeutic drugs. Therefore, there is an urgent need to explore vulnerabilities of triple-negative breast cancer and develop novel therapeutic drugs to improve clinical outcomes for triple-negative breast cancer patients. Metabolic reprogramming may provide promising therapeutic targets for the treatment of triple-negative breast cancer. In this paper, we primarily discuss how triple-negative breast cancer cells reprogram their metabolic phenotype and that of stromal cells in the microenvironment to survive under nutrient-poor conditions. Considering that metastasis and chemoresistance are the main contributors to mortality in triple-negative breast cancer patients, we also focus on the role of metabolic adaption in mediating metastasis and chemoresistance of triple-negative breast cancer tumors.https://www.frontiersin.org/article/10.3389/fonc.2020.00428/fulltriple negative breast neoplasmsmetabolic networks and pathwaysneoplasm metastasistumor microenvironmentglycolysis |
| spellingShingle | Xiangyu Sun Mozhi Wang Mengshen Wang Xueting Yu Jingyi Guo Tie Sun Xinyan Li Litong Yao Haoran Dong Yingying Xu Metabolic Reprogramming in Triple-Negative Breast Cancer Frontiers in Oncology triple negative breast neoplasms metabolic networks and pathways neoplasm metastasis tumor microenvironment glycolysis |
| title | Metabolic Reprogramming in Triple-Negative Breast Cancer |
| title_full | Metabolic Reprogramming in Triple-Negative Breast Cancer |
| title_fullStr | Metabolic Reprogramming in Triple-Negative Breast Cancer |
| title_full_unstemmed | Metabolic Reprogramming in Triple-Negative Breast Cancer |
| title_short | Metabolic Reprogramming in Triple-Negative Breast Cancer |
| title_sort | metabolic reprogramming in triple negative breast cancer |
| topic | triple negative breast neoplasms metabolic networks and pathways neoplasm metastasis tumor microenvironment glycolysis |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.00428/full |
| work_keys_str_mv | AT xiangyusun metabolicreprogrammingintriplenegativebreastcancer AT mozhiwang metabolicreprogrammingintriplenegativebreastcancer AT mengshenwang metabolicreprogrammingintriplenegativebreastcancer AT xuetingyu metabolicreprogrammingintriplenegativebreastcancer AT jingyiguo metabolicreprogrammingintriplenegativebreastcancer AT tiesun metabolicreprogrammingintriplenegativebreastcancer AT xinyanli metabolicreprogrammingintriplenegativebreastcancer AT litongyao metabolicreprogrammingintriplenegativebreastcancer AT haorandong metabolicreprogrammingintriplenegativebreastcancer AT yingyingxu metabolicreprogrammingintriplenegativebreastcancer |